|
1
|
Weiss N, Heydrick SJ, Postea O, Keller C,
Keaney JF Jr and Loscalzo J: Influence of hyperhomocysteinemia on
the cellular redox state - impact on homocysteine-induced
endothelial dysfunction. Clin Chem Lab Med. 41:1455–1461. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Landmesser U, Spiekermann S, Dikalov S, et
al: Vascular oxidative stress and endothelial dysfunction in
patients with chronic heart failure: role of xanthine-oxidase and
extracellular superoxide dismutase. Circulation. 106:3073–3078.
2002. View Article : Google Scholar
|
|
3
|
Forgione MA, Leopold JA and Loscalzo J:
Roles of endothelial dysfunction in coronary artery disease. Curr
Opin Cardiol. 15:409–415. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eyries M, Collins T and Khachigian LM:
Modulation of growth factor gene expression in vascular cells by
oxidative stress. Endothelium. 11:133–139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harrison D, Griendling KK, Landmesser U,
Hornig B and Drexler H: Role of oxidative stress in
atherosclerosis. Am J Cardiol. 91:7A–11A. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Prasad K and Lee P: Suppression of
oxidative stress as a mechanism of reduction of
hypercholesterolemic atherosclerosis by aspirin. J Cardiovasc
Pharmacol Ther. 8:61–69. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vassalle C, Petrozzi L, Botto N, Andreassi
MG and Zucchelli GC: Oxidative stress and its association with
coronary artery disease and different atherogenic risk factors. J
Intern Med. 256:308–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Futterman LG and Lemberg L: Statin
pleiotropy: fact or fiction? Am J Crit Care. 13:244–249.
2004.PubMed/NCBI
|
|
9
|
Bell RM and Yellon DM: Atorvastatin,
administered at the onset of reperfusion, and independent of lipid
lowering, protects the myocardium by up-regulating a pro-survival
pathway. J Am Coll Cardiol. 41:508–515. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soner BC, Murat N, Demir O, Guven H, Esen
A and Gidener S: Evaluation of vascular smooth muscle and corpus
cavernosum on hypercholesterolemia. Is resveratrol promising on
erectile dysfunction? Int J Impot Res. 22:227–233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sinzinger H, Chehne F and Lupattelli G:
Oxidation injury in patients receiving HMG-CoA reductase
inhibitors: occurrence in patients without enzyme elevation or
myopathy. Drug Saf. 25:877–883. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Parker RA, Huang Q and Tesfamariam B:
Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase
inhibitors on endothelial nitric oxide synthase and the formation
of oxidants in the vasculature. Atherosclerosis. 169:19–29. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Satoh K, Yamato A, Nakai T, Hoshi K and
Ichihara K: Effects of 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors on mitochondrial respiration in ischaemic dog
hearts. Br J Pharmacol. l16:1894–1898. 1995. View Article : Google Scholar
|
|
14
|
Ichihara K, Satoh K, Yamamoto A and Hoshi
K: Are all HMG-CoA reductase inhibitors protective against ischemic
heart disease? Nippon Yakurigaku Zasshi. 114(Suppl 1): 142P–l49P.
1999.(In Japanese).
|
|
15
|
März W, Siekmeier R, Müller HM, Wieland H,
Gross W and Olbrich HG: Effects of lovastatin and pravastatin on
the survival of hamsters with inherited cardiomyopathy. J
Cardiovasc Pharrnacol Ther. 5:275–279. 2000.PubMed/NCBI
|
|
16
|
Pisarenko OI, Studneva IM, Lankin VZ, et
al: Inhibitor of beta-hydroxy-beta-methylglutaryl coenzyme A
reductase decreases energy supply to the myocardium in rats. Bull
Exp Biol Med. 132:956–958. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sahin AS, Görmüş N and Duman A:
Preconditioning with levosimendan prevents contractile dysfunction
due to H2O2-induced oxidative stress in human
myocardium. J Cardiovasc Pharmacol. 50:419–423. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McQuaid KE, Smyth EM and Keenan AK:
Evidence for modulation of hydrogen peroxide-induced endothelial
barrier dysfunction by nitric oxide in vitro. Eur J Pharmacol.
307:233–241. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Barlow RS, El-Mowafy AM and White RE:
H(2)O(2) opens BK(Ca) channels via the PLA(2)-arachidonic acid
signaling cascade in coronary artery smooth muscle. Am J Physiol
Heart Circ Physiol. 279:H475–H483. 2000.PubMed/NCBI
|
|
20
|
Lacy F, O’Connor DT and Schmid-Schönbein
GW: Plasma hydrogen peroxide production in hypertensives and
normotensive subjects at genetic risk of hypertension. J Hypertens.
16:291–303. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Halliwell B, Clement MV and Long LH:
Hydrogen peroxide in the human body. FEBS Lett. 486:10–13. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lankin VZ, Tikhaze AK, Kaminnaia VI,
Kaminnyĭ AI, Konovalova GG and Kukharchuk VV: Intensification in
vivo of free radical oxidation of low density lipoproteins in
plasma from patients with myocardial ischemia treated by
HMG-CoA-reductase pravastatin and suppression of lipid peroxidation
by ubiquinone Q10. Biull Eksp Biol Med. 129:176–179. 2000.(In
Russian).
|
|
23
|
Lankin VZ, Tikhaze AK, Kukharchuk VV, et
al: Antioxidants decreases the intensification of low density
lipoprotein in vivo peroxidation during therapy with statins. Mol
Cell Biochem. 249:129–140. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lankin VZ and Tikhaze AK: Atherosclerosis
as a free radical pathology and antioxidative therapy of this
disease. Free Radicals, Nitric Oxide, and Inflammation: Molecular,
Biochemical, and Clinical Aspects. Tomasi A, Özben T and Skulachev
VP: (NATO Science Series). 344. IOS Press; Amsterdam: pp. 218–231.
2003
|
|
25
|
Robicsek F and Schaper J: Reperfusion
injury: fact or myth? J Card Surg. 12:133–137. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thomas MK, Narang D, Lakshmy R, Gupta R,
Naik N and Maulik SK: Correlation between inflammation and
oxidative stress in normocholesterolemic coronary artery disease
patients ‘on’ and ‘off’ atorvastatin for short time intervals.
Cardiovasc Drugs Ther. 20:37–44. 2006.PubMed/NCBI
|
|
27
|
Wassmann S, Ribaudo N, Faul A, Laufs U,
Böhm M and Nickenig G: Effect of atorvastatin 80 mg on endothelial
cell function (forearm blood flow) in patients with pretreatment
serum low-density lipoprotein cholesterol levels <130 mg/dl. Am
J Cardiol. 93:84–88. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sugiyama M, Ohashi M, Takase H, Sato K,
Ueda R and Dohi Y: Effects of atorvastatin on inflammation and
oxidative stress. Heart Vessels. 20:133–136. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Marketou ME, Zacharis EA, Nikitovic D, et
al: Early effects of simvastatin versus atorvastatin on oxidative
stress and proinflammatory cytokines in hyperlipidemic subjects.
Angiology. 57:211–218. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Argüelles S, Garcia S, Maldonado M,
Machado A and Ayala A: Do the serum oxidative stress biomarkers
provide a reasonable index of the general oxidative stress status?
Biochim Biophys Acta. 1674:251–259. 2004.PubMed/NCBI
|
|
31
|
Hargreaves IP, Duncan AJ, Heales SJ and
Land JM: The effect of HMG-CoA reductase inhibitors on coenzyme
Q10: possible biochemical/clinical implications. Drug Saf.
28:659–676. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li YG, Zhu W, Tao JP, et al: Resveratrol
protects cardiomyocytes from oxidative stress through SIRT1 and
mitochondrial biogenesis signaling pathways. Biochem Biophys Res
Commun. 438:270–276. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cai H and Harrison DG: Endothelial
dysfunction in cardiovascular diseases: the role of oxidant stress.
Circ Res. 87:840–844. 2000. View Article : Google Scholar : PubMed/NCBI
|
